Exogenous Administration of Microsomes-associated Alpha-synuclein Aggregates to Primary Neurons As a Powerful Cell Model of Fibrils Formation
June 26th, 2018
11.6K views
The goal of this protocol is to provide a cell-based system that replicates the formation of alpha-synuclein aggregates in vivo. Intracellular alpha-synuclein inclusions are seeded in primary neurons by the internalization and propagation of exogenous administered native microsomes-associated alpha-synuclein aggregates isolated from diseased alpha-synuclein transgenic mice.
Overview
This study presents a cell-based model for investigating the in vivo formation of alpha-synuclein aggregates, utilizing primary neurons. By employing exogenously administered alpha-synuclein aggregates from diseased transgenic mice, the research seeks to elucidate the mechanisms underlying aggregation spreading and toxicity.
Key Study Components
Area of Science
- Neuroscience
- Cell Biology
- Neurodegenerative Diseases
Background
- Alpha-synuclein is implicated in neurodegenerative diseases.
- Understanding its aggregation process is critical for therapeutic interventions.
- Current methods for studying aggregation often require extensive purification.
Purpose of Study
- To develop a simplified protocol for studying alpha-synuclein aggregation.
- To investigate the propagation and toxicity of alpha-synuclein aggregates in neuronal environments.
- To provide a reliable system that bypasses the need for complex purification processes.
Methods Used
- The study utilizes primary neuron cultures to examine intracellular aggregation.
- Microcentrifugation and ultracentrifugation are employed to isolate microsomes-associated alpha-synuclein from diseased transgenic mice.
- Western blotting and immunofluorescence assays are used to analyze protein aggregates.
- Neurons are treated with aggregates over a two-week timeline, with media changes every three days.
Main Results
- The treatment with alpha-synuclein aggregates leads to a time-dependent formation of distinct inclusions in neurons.
- Initially appearing as scattered puncta, these aggregates develop into more mature structures over time.
- The presence of these inclusions was confirmed using aggregate-specific antibodies.
Conclusions
- The study demonstrates a novel approach to modeling alpha-synuclein aggregation in vitro.
- This method enhances understanding of the mechanisms behind alpha-synuclein pathology.
- The findings have significant implications for future research on neurodegenerative diseases and potential therapeutic strategies.
Frequently Asked Questions
What are the advantages of this cell-based model?
This model allows for the direct observation of alpha-synuclein aggregation in a relevant neuronal environment without the need for prior purification of aggregates.
How is the alpha-synuclein aggregation model implemented?
The model involves treating primary neurons with microsomes-associated alpha-synuclein aggregates derived from diseased transgenic mice, allowing for examination of in vivo-like conditions.
What types of data are obtained from this method?
The method generates molecular data related to the presence of alpha-synuclein aggregates, as well as insights into their toxicological effects on neuronal health.
How can this method be adapted for other studies?
This approach can be tailored by using different neuronal cell types or various forms of pathogenic aggregates to study their specific aggregation behavior and toxicity.
What limitations should be considered when using this model?
While the model provides valuable insights, it may not fully replicate all aspects of in vivo conditions, such as cellular interactions and full environmental context of the brain.
What are the implications of these findings for neurodegenerative diseases?
These findings contribute to the understanding of alpha-synuclein's role in neurodegeneration and may inform future therapeutic strategies targeting aggregation processes.
Executive Industry Relevance
This method provides a physiologically relevant cell model for studying pathogenic alpha-synuclein aggregation directly from diseased tissue, bypassing recombinant fibril production. It enables mechanistic de-risking of alpha-synuclein-targeted therapeutics by using authentic seeding species that mimic in vivo inclusions. The approach supports target validation and phenotypic screening in Parkinson's disease research with improved predictive confidence.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses using endogenous, disease-derived alpha-synuclein aggregates.
- Operational Value: Eliminates time-consuming recombinant fibril purification, accelerating target engagement studies.
- Predictive Value: Uses pathogenic seeding species isolated from transgenic mice, improving translational relevance for target confidence.
Screening & Assay Development
- Scientific Value: Generates quantifiable, time-dependent intracellular inclusions positive for aggregated and phosphorylated alpha-synuclein.
- Operational Value: Produces a standardized, reproducible readout for compound screening in primary neurons.
- Assay Readiness: Supports scalable platform development for evaluating aggregation inhibitors or modulators.
Translational & Preclinical Research
- Scientific Value: Models intracellular inclusion formation that colocalizes with presynaptic and neurite markers, reflecting pathogenic spread.
- Operational Value: Enables longitudinal tracking of aggregation over two weeks with defined media replenishment.
- Translational Continuity: Bridges in vitro findings to in vivo-like pathology using tissue-derived aggregates from diseased models.
Pipeline & Workflow Integration
The method fits within the early discovery continuum, supporting target validation through phenotypic screening of aggregation modulators in a disease-relevant neuronal system.
- Discovery Biology: Facilitates hypothesis testing on aggregation mechanisms and toxicity using authentic seeding species.
- Screening: Provides assay-ready neuronal cultures with quantifiable inclusion formation as a functional readout.
- Analytics: Enables Western blot and immunofluorescence detection of aggregate-specific and phosphorylated alpha-synuclein.
- Translational Research: Uses microsomes-associated aggregates from diseased tissue to enhance preclinical predictive value.
- Enterprise Reuse: Establishes a reusable neuronal model for iterative target de-risking across alpha-synuclein-focused programs.
Operational & Enterprise Impact
- Scientific Value: Predictive confidence in target validation via disease-relevant, endogenous alpha-synuclein species.
- Operational Value: Standardized isolation and administration protocol improves reproducibility across labs.
- Strategic Value: Reduces biological risk in lead identification by using pathogenic aggregates over artificial fibrils.
- Portfolio Impact: Enables risk-adjusted prioritization of targets based on aggregation inhibition in a physiologic model.
Implementation Considerations
- Requires expertise in primary neuron culture and subcellular fractionation techniques.
- Dependent on access to transgenic mouse tissue rich in pathological alpha-synuclein inclusions.
- Necessitates ultracentrifugation equipment for microsomes-associated aggregate isolation.
- Requires optimization of aggregate-to-neuron ratio based on plating density.
- Limited by tissue availability and need for fresh or frozen diseased tissue sources.
Biopharma FAQs
Why use microsomes-associated alpha-synuclein aggregates for target validation?
These aggregates are endogenous, pathogenic species isolated from diseased transgenic mice, ensuring authentic seeding activity that mimics in vivo inclusions. Unlike recombinant fibrils, they reflect the biochemical complexity of patient-derived pathology. This improves target validation confidence by using a biologically relevant trigger of aggregation.
How does isolating microsomes-associated alpha-synuclein fit the discovery pipeline?
The differential centrifugation protocol enriches for vesicle-associated alpha-synuclein species implicated in cellular toxicity and spread. This isolation step enables consistent production of a defined, bioactive fraction for neuronal treatment. It supports early discovery by providing a standardized, pathogenic input for target engagement assays.
What quantitative dependent variable measurements enable screening readiness?
The method yields time-dependent formation of intracellular inclusions detectable by aggregate-specific and phosphorylated alpha-synuclein antibodies. These inclusions progress from scattered puncta to mature neurite-associated structures over two weeks. This provides a quantifiable, imaging-compatible readout for high-content screening of aggregation modulators.
Why do replication requirements matter for cross-functional collaboration?
Consistent inclusion formation depends on precise tissue sourcing, centrifugation parameters, and aggregate-to-neuron ratios. Standardizing these variables ensures reproducible results across teams and sites. This reproducibility is essential for assay transfer between discovery, preclinical, and translational science groups.
What statistical analysis capabilities are required before implementation?
Implementation requires baseline characterization of inclusion formation kinetics and variability across neuronal preparations. Teams must establish statistical power for detecting changes in inclusion burden or morphology. This enables robust comparison of treatment effects in screening or target validation campaigns.
Chapters in this video
0:04
Title
0:36
Isolation of Microsomes-associated Alpha-synuclein Aggregates from Diseased A53T Alpha-synuclein Transgenic Mic
2:30
Western Blot
4:32
Neurons Treatment
5:40
Immunofluorescence
7:45
Results: Time-dependent Induction of Alpha-synuclein Deposition After Administration of Microsomes-associated Alpha-synuclein Aggregates
8:35
Conclusion
